{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:10Z","timestamp":1794438490600,"version":"4.9.1"},"reference-count":33,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0501-8","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T09:13:19Z","timestamp":1549617199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma"],"prefix":"10.1136","volume":"7","author":[{"given":"Mohammed","family":"Alnaggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kecheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"501_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"501_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"501_CR3","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.5858\/134.4.e8","volume":"134","author":"MK Washington","year":"2010","unstructured":"Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN. Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts. Arch Pathol Lab Med. 2010;134:e8\u201313.","journal-title":"Arch Pathol Lab Med"},{"key":"501_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/00000658-199411000-00007","volume":"220","author":"PA Lipsett","year":"1994","unstructured":"Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann Surg. 1994;220:644\u201352.","journal-title":"Ann Surg"},{"key":"501_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/hep.510270201","volume":"27","author":"A Bergquist","year":"1998","unstructured":"Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998;27:311\u20136.","journal-title":"Hepatology"},{"key":"501_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","volume":"8","author":"B Blechacz","year":"2011","unstructured":"Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"501_CR7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.15403\/jgld.2014.1121.244.chl","volume":"24","author":"I Bartella","year":"2015","unstructured":"Bartella I, Dufour JF. Clinical diagnosis and staging of intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis. 2015;24:481\u20139.","journal-title":"J Gastrointestin Liver Dis"},{"key":"501_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115\u201325.","journal-title":"Semin Liver Dis"},{"key":"501_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","volume":"31","author":"JC Chavez","year":"2018","unstructured":"Chavez JC, Locke FL. CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018;31:135\u201346.","journal-title":"Best Pract Res Clin Haematol"},{"key":"501_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"501_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.12090","volume":"160","author":"MS Braza","year":"2013","unstructured":"Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol. 2013;160:123\u201332.","journal-title":"Br J Haematol"},{"key":"501_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph8010040","volume":"8","author":"H Kobayashi","year":"2015","unstructured":"Kobayashi H, Tanaka Y. gammadelta T cell immunotherapy-a review. Pharmaceuticals (Basel). 2015;8:40\u201361.","journal-title":"Pharmaceuticals (Basel)"},{"key":"501_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","volume":"34","author":"M Sakamoto","year":"2011","unstructured":"Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother. 2011;34:202\u201311.","journal-title":"J Immunother"},{"key":"501_CR14","doi-asserted-by":"crossref","unstructured":"Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D\u2019Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450\u20137457.","DOI":"10.1158\/0008-5472.CAN-07-0199"},{"key":"501_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","volume":"57","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Negrier S. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1599\u2013609.","journal-title":"Cancer Immunol Immunother"},{"key":"501_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007;56:469\u201376.","journal-title":"Cancer Immunol Immunother"},{"key":"501_CR17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","volume":"60","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K, Phase I. II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother. 2011;60:1075\u201384.","journal-title":"Cancer Immunol Immunother"},{"key":"501_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1215\/15228517-2008-111","volume":"11","author":"NL Bryant","year":"2009","unstructured":"Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS Jr. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro-Oncology. 2009;11:357\u201367.","journal-title":"Neuro-Oncology"},{"key":"501_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","volume":"11","author":"Z Li","year":"2011","unstructured":"Li Z, Xu Q, Peng H, Cheng R, Sun Z, Ye Z. IFN-gamma enhances HOS and U2OS cell lines susceptibility to gammadelta T cell-mediated killing through the Fas\/Fas ligand pathway. Int Immunopharmacol. 2011;11:496\u2013503.","journal-title":"Int Immunopharmacol"},{"key":"501_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jor.21579","volume":"30","author":"Z Li","year":"2012","unstructured":"Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to Vgamma9Vdelta2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012;30:824\u201330.","journal-title":"J Orthop Res"},{"key":"501_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville M, O\u2019Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467\u201378.","journal-title":"Nat Rev Immunol"},{"key":"501_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","volume":"32","author":"YH Chien","year":"2014","unstructured":"Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121\u201355.","journal-title":"Annu Rev Immunol"},{"key":"501_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1084\/jem.20030584","volume":"198","author":"Y Gao","year":"2003","unstructured":"Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198:433\u201342.","journal-title":"J Exp Med"},{"key":"501_CR24","doi-asserted-by":"publisher","first-page":"e27572","DOI":"10.4161\/onci.27572","volume":"3","author":"JP Fisher","year":"2014","unstructured":"Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology. 2014;3:e27572.","journal-title":"Oncoimmunology"},{"key":"501_CR25","doi-asserted-by":"crossref","unstructured":"Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, Zhang W. gammadelta T cells and their potential for immunotherapy. Int J Biol Sci. 2014;10:119\u201335.","DOI":"10.7150\/ijbs.7823"},{"key":"501_CR26","first-page":"1","volume":"8","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Tu W. Dual face of V\u03b39V\u03b42-T cells in tumor immunology: anti- versus pro-tumoral activities. Front Immunol. 2017;8:1\u201313.","journal-title":"Front Immunol"},{"key":"501_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.smim.2010.04.004","volume":"22","author":"S Nedellec","year":"2010","unstructured":"Nedellec S, Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: from signals to functions. Semin Immunol. 2010;22:199\u2013206.","journal-title":"Semin Immunol"},{"key":"501_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1189\/jlb.3RU0914-443R","volume":"97","author":"S Paul","year":"2015","unstructured":"Paul S, Shilpi, Lal G. Role of gamma-delta (gammadelta) T cells in autoimmunity. J Leukoc Biol. 2015;97:259\u201371.","journal-title":"J Leukoc Biol"},{"key":"501_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","volume":"296","author":"EJ Adams","year":"2015","unstructured":"Adams EJ, Gu S, Luoma AM. Human gamma delta T cells: evolution and ligand recognition. Cell Immunol. 2015;296:31\u201340.","journal-title":"Cell Immunol"},{"key":"501_CR30","first-page":"512","volume":"5","author":"MW Khan","year":"2014","unstructured":"Khan MW, Eberl M, Moser B. Potential use of gammadelta T cell-based vaccines in cancer immunotherapy. Front Immunol. 2014;5:512.","journal-title":"Front Immunol"},{"key":"501_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","volume":"66","author":"P Wrobel","year":"2007","unstructured":"Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol. 2007;66:320\u20138.","journal-title":"Scand J Immunol"},{"key":"501_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.intimp.2013.01.022","volume":"16","author":"D Kabelitz","year":"2013","unstructured":"Kabelitz D, Peters C, Wesch D, Oberg HH. Regulatory functions of gammadelta T cells. Int Immunopharmacol. 2013;16:382\u20137.","journal-title":"Int Immunopharmacol"},{"key":"501_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","volume":"38","author":"G Chitadze","year":"2017","unstructured":"Chitadze G, Oberg HH, Wesch D, Kabelitz D. The ambiguous role of gammadelta T lymphocytes in antitumor immunity. Trends Immunol. 2017;38:668\u201378.","journal-title":"Trends Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0501-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T12:34:59Z","timestamp":1662899699000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0501-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0501-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"3 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol received ethical approval from the Regional Ethics Committee of Guangzhou Fuda Cancer Hospital, China. Written informed consent was obtained from participant in accordance with the Declaration of Helsinki, and\n                      \n                      ID: NCT02425735.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The IND for allogenic \u03b3\u03b4 T cell application in clinical therapy is filling in both PR China and USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}